On January 22, 2021, ICER released its Draft Evidence Report entitled, “Belimumab and Voclosporin for Lupus Nephritis: Effectiveness and Value.” Patients Rising Now submitted comments on the draft report. Some of the concerns raised in the letter include the report’s failure to contextualize quality-of-life issues for lupus nephritis patients and its narrow focus on nephritis only as a sequela of lupus. The letter also notes that the report made assumptions about the price of voclosporin based on outdated data. To read Patients Rising Now’s full comments, click here.